Lifestyle

Oxford trial claims dosing regime 90 per cent effective against COVID-19

Oxford trial claims dosing regime 90 per cent effective against COVID-19
The chief investigator of the Oxford coronavirus vaccine trial says one of its dosing regimens could be highly effective against COVID-19.
"Excitingly, we've found that one of our dosing regimens may be around 90 per cent effective," Professor Andrew Polland told Sky News UK.
"And if this dosing regime is used, more people could be vaccinated with planned vaccine supply."
Results published by the media outlet claimed individuals who were given a half dose of the Oxford vaccine followed by a full dose a month later showed an efficacy rate of 90 per cent.
Pfizer and BioNTech say their final analysis shows coronavirus vaccine is 95 per cent effective with no safety concerns. (CNN)
Though, when individuals were given two full doses a month apart, the vaccine had an effective rate of 62 per cent.
The vaccine was developed by Oxford University and pharmaceutical company AstraZeneca and is one of three known treatments being trialled during the pandemic.
The two others are Pfizer which claims to have a 95 per cent preventative rate against the virus and Moderna which claims its vaccine has a 94.5 per cent effective rate.
The fresh claims about the Oxford vaccine's abilities comes two months after it was put on hold after a participant in a UK trial suffered an adverse reaction.
The Oxford trial is one of two candidates in a $1.7 billion deal signed by the Federal Government to roll out COVID-19 vaccines to Australians next year.
Screen grab taken from video issued by Britain's Oxford University, showing a person being injected as part of the first human trials in the UK to test a potential coronavirus vaccine. (AP)
The Oxford vaccine includes people 70 years and older, which naturally increases the risk of temporally associated with adverse results.
Meanwhile, new Australian research has found immunity against coronavirus can last up to eight months after infection.
The study, by Monash University's Department of Immunology and Pathology and Alfred Research Alliance, uncovered a memory B cell which "remembers" the virus and triggers the production of protective antibodies if re-exposed.